Fusion Pharmaceuticals to be acquired by AstraZeneca
Canadian Manufacturing
MARCH 19, 2024
HAMILTON and BOSTON — Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing radioconjugates (RCs) as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. It also strengthens their presence in Canada.
Let's personalize your content